• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice

    2016-12-01 09:23:41ChengyouZhengBaojianGuoWeiCaiWeiCuiShinghungMakYuqiangWangSimonMingyuenLeeYifanHanZaijunZhangInstituteofNewDrugResearchandGuangzhouKeyLaboratoryofInnovativeChemicalDrugResearchinCardiocerebrovascularDiseasesJinan

    Cheng-you Zheng, Bao-jian Guo, Wei Cai, Wei Cui, Shing-hung Mak, Yu-qiang Wang, Simon Ming-yuen Lee, Yi-fan Han,, Zai-jun Zhang, Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong Province, China School of Medicine, Ningbo University, Ningbo, Zhejiang Province, China Department of Applied Biology and Chemical Technology, Institute of Modern Chinese Medicine, The Hong Kong Polytechnic University, Hung Hom, Hong Kong Special Administrative Region, China State Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao Special Administrative Region, China

    No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice

    Cheng-you Zheng1, Bao-jian Guo1, Wei Cai1, Wei Cui2, Shing-hung Mak3, Yu-qiang Wang1, Simon Ming-yuen Lee4, Yi-fan Han3,*, Zai-jun Zhang1,*
    1 Institute of New Drug Research and Guangzhou Key Laboratory of Innovative Chemical Drug Research in Cardiocerebrovascular Diseases, Jinan University College of Pharmacy, Guangzhou, Guangdong Province, China
    2 School of Medicine, Ningbo University, Ningbo, Zhejiang Province, China
    3 Department of Applied Biology and Chemical Technology, Institute of Modern Chinese Medicine, The Hong Kong Polytechnic University, Hung Hom, Hong Kong Special Administrative Region, China
    4 State Key Laboratory of Quality Research of Chinese Medicine and Institute of Chinese Medical Sciences, University of Macau, Taipa, Macao Special Administrative Region, China

    How to cite this article: Zheng CY, Guo BJ, Cai W, Cui W, Mak SH, Wang YQ, Lee SMY, Han YF, Zhang ZJ (2016) No synergism between bis(propyl)-cognitin and rasagiline on protecting dopaminergic neurons in Parkinson's disease mice. Neural Regen Res 11(8)∶1339-1346.

    Funding: This study was supported by grants from the Natural Science Foundation of Guangdong Province of China, No. 2015A030313317; a grant from the Science and Technology Program of Guangzhou City of China, No. 2014J4100097; and partially by a grant from the Science and Technology Development Fund (FDCT) of Macao Special Administrative Region, No. 134/2014/A3; a grant from the Research Committee of University of Macau, No. MYRG139(Y1-L4)-ICMS12-LMY and MYRG2015-00214-ICMS-QRCM; and grants from the Research Grants Council of Hong Kong Special Administrative Region of China, No. 561011, 15101014; the Hong Kong Polytechnic University of China, No. G-SB10, G-UC15 and G-YBGQ.

    Zai-jun Zhang, M.D. or

    Yi-fan Han,

    zaijunzhang@163.com or bcyfhan@polyu.edu.hk.

    orcid:

    0000-0002-0690-1673

    (Zai-jun Zhang)

    Accepted: 2016-06-08

    Graphical Abstract

    Rasagiline, a monoamine oxidase-B inhibitor, and bis(propyl)-cognitin (B3C), a novel dimer are reported to be neuroprotective. Herein, the synergistical neuroprotection produced by rasagiline and B3C was investigated in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced mice of Parkinsonism. By using neurobehavioural tests, high-performance liquid chromatography and western blot assay, we showed that B3C at 0.3 mg/kg, rasagiline at 0.02 mg/kg, as well as co-treatment with B3C and rasagiline prevented MPTP-induced behavioural abnormities, increased the concentrations of dopamine and its metabolites in the striatum, and up-regulated the expression of tyrosine hydroxylase in the substantia nigra. However, the neuroprotective effects of co-treatment were not significantly improved when compared with those of B3C or rasagiline alone. Collectively, we have demonstrated that B3C at 0.3 mg/kg and rasagline at 0.02 mg/kg could not produce synergistic neuroprotective effects.

    nerve regeneration; Parkinson's disease; bis(propyl)-cognitin; rasagiline; monoamine oxidase B; dopamine; multitarget; synergism; neuroprotection; neural regeneration

    Introduction

    Parkinson’s disease (PD), the second most common neurodegenerative disorder, has emerged as one of the major public health problems worldwide (Jeanjean and Aubert, 2011). Unfortunately, the exact molecular pathology of PD remains to be elucidated. Currently used medications such as dopamine precursor (levodopa), dopamine agonists and monoamine oxidase-B (MAO-B) inhibitors (selegiline and rasagiline), are reported to have modest symptomatic benefits without obvious disease-modifying potential, because their primary target is not dopaminergic neuronal loss (Smith, 2010; Meissner et al., 2011). The ideal PD therapy aims to produce neuroprotective effects, concurrently relieve PD-associated symptoms and delay the loss of dopaminergic neurons in the substantia nigra (Schapira, 2004).

    Rasagiline (Figure 1), a second-generation MAO-B inhibitor, has been approved by US Food and Drug Administration (FDA) for the treatment of PD (Degli Esposti et al., 2015). Rasagiline is reported to produce neuroprotective effects in various experimental models both in vitro and in vivo (Naoi et al., 2013). Interestingly, the neuroprotective effects of rasagiline might be associated with its anti-apoptotic activities rather than its MAO-B inhibition property (Youdim et al., 2001). However, the request for an on-label indication of rasagiline for neuroprotection in PD has been repeatedly denied by FDA, because there is limited evidence to prove its neuroprotective effects in clinical trials (Ahlskog and Uitti, 2010).

    Bis(propyl)-cognitin (B3C; Figure 1), in which two tacrine moieties were linked by three methylene (-CH2-) group, was originally synthesized as a novel acetylcholinesterase (AChE) inhibitor (Carlier et al., 1999). We have previously demonstrated the neuroprotective effects of B3C in various in vivo models of neurodegenerative disorders (Luo et al., 2010; Han et al., 2012). B3C was also reported to protect against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neuronal loss and Parkinsonian motor defects in mice (Yao et al., 2012). The neuroprotective effects of B3C are reported to be associated with its AChE inhibition (Carlier et al., 1999), myocyte enhancer factor-2D (MEF2D) enhancement (Yao et al., 2012), as well as uncompetitive N-methyl-D-aspartate receptor antagonism (Luo et al., 2010).

    Considering the multi-factorial etiological nature of PD (Calabresi and Di Filippo, 2015), multiple drug therapy might offer a new hope by addressing complex pathological aspects. The combination of drug molecules with different modes of action could concurrently act on multiple targets and/or biological processes which cause the chronic and progressive neurodegeneration in PD (Reznichenko et al., 2010; Zhang et al., 2015). In the light of this rationale, we investigated whether the post-MPTP loss of dopaminergic neurons could be additively/synergistically restored by a combination of rasagiline and B3C. We also examined whether MPTP-induced behavioral abnormities and biochemcial changes could be reversed by these compounds.

    Materials and Methods

    Ethics statement

    Animal treatment and maintenance were carried out in accordance with the guidelines established by the National Institutes of Health for the Care and Use of Laboratory Animals and were approved by the Ethics Committee of Jinan University in China (Ethical approval No. EAEJNU-2013-0117). Precautions were taken to minimize suffering and the number of animals used in the study.

    Treatments

    Fifty-six specific-pathogen-free male C57BL/6 mice (25 ± 2 g and 7-8 weeks old) were purchased from the Animal Center of Guangdong Province in China (Certification No. SCXK (Yue)-2013-0002). Mice were housed under a 12-hour light/dark cycle, and allowed to acclimate for 7 days before treatment. Mice were randomly divided into seven groups (control, MPTP, MPTP + 0.3 mg/kg B3C, MPTP + 1 mg/kg B3C, MPTP + 0.02 mg/kg rasagiline, MPTP + 0.1 mg/kg rasagiline, and MPTP + 0.3 mg/kg B3C + 0.02 mg/kg rasagiline groups). Mice in the control group received saline (0.1 mL/10 mg). The remaining mice were given MPTP (30 mg/kg/day, Sigma-Aldrich, St. Louis., MO, USA) intraperitoneally once daily for 5 consecutive days to induce Parkinsonism. Resting period (3 days) was allowed for the conversion of MPTP to MPP+(Tatton and Greenwood, 1991). On day 8, B3C (0.3, 1 mg/kg), rasagiline (0.02, 0.1 mg/kg) (Sigma-Aldrich), or B3C (0.3 mg/kg) + rasagiline (0.02 mg/kg) were administered intragastrally once daily for 7 consecutive days according to the grouping. Mice in the control group or the MPTP group received equal volume of saline (0.1 mL/10 mg).

    Behavioral analysis

    On day 15, after final drug treatment, a serial of tests including catalepsy, pole, rotarod and foot-printing tests was used to analyze different aspects of Parkinsonism, such as hypokinetic disorder, rigidity and problem with gait (difficulty in walking). These tests were performed between 9 a.m. and 2 p.m. under normal room lighting. Behavioral experiments were randomized and blinded by an independent researcher.

    The catalepsy test was performed according to a previous publication (Sedelis et al., 2001), by placing the forepaws of mice on a horizontal metal bar (2 mm in diameter), 15 cm above the tabletop. The duration until one of the hind paws caught the metal bar was recorded. The average of duration of three successive trials was measured. Between each trial, animals were allowed to rest for 1 minute.

    The pole test was adapted from Ogawa et al. (1985). The pole test consisted of a 50 cm high steel pole, 0.5 cm in diameter, and wrapped with gauze to prevent slipping and the base position in the home cage. A rubber ball was glued on the top of the pole to prevent animals from sitting on the top and to help position the animals on the pole (by sliding the forepaws over the ball and holding the animal by the tail). The time that animals required to climb down the pole was measured. During pre-training as well as post-MPTP sessions, each animal was subjected to three successive trials,with a 10-minute interval. The average time of three trials was used for statistical analyses.

    Rotarod test was used to measure motor balance and coordination (Bao et al., 2012). Mice were placed on rotating rod with 3 cm diameter (Rotarod for mice, ZH-YLS-4C, Zhenghua, Anhui Province, China). Tested animals were separated by large disks. After the mice were placed on the rod at constant rotational speed of 5 r/min, the trial was started and rotational speed was automatically increased from 5 to 30 r/min within 5 minutes. The trial stopped when the mouse fell down, activating a switch that automatically stopped a timer, or when 5 minutes were completed. Mice were pre-trained on the rotarod for 3 consecutive days before MPTP treatment in order to reach a stable performance. The final test was performed in three sessions with an interval of 30 minutes. Rotarod performances in three sessions were recorded, and the average time on the rotarod was compared among groups.

    For the footprint test, we followed the procedure described by Richter et al. (2007). Mice were first trained to pass straight forward through the wood corridor (5 cm wide, 85 cm long). Then mice with their forepaws with black ink colored and hindpaws with red ink colored were placed into the corridor. Their footsteps were recorded on a white absorbing paper. The duration of mice crossing the corridor was recorded, stride length and step width were also measured. Three trials were carried out and the results were averaged.

    Tissue processing

    After behavioral testing, animals were sacrificed by a 0.5 mL/10 g intraperitoneal injection of 10% chloral hydrate. The tissues of striatum and substantia nigra (Hayley et al., 2004; Jackson-Lewis and Przedborski, 2007) were dissected rapidly on ice and frozen in liquid nitrogen. Tissues were stored at -80°C until processed for high-pressure liquid chromatography (HPLC) or western blot assay.

    Determination of dopamine and its metabolites, homovanilic acid (HVA) and 3,4-dihydroxyphenylacetic acid (DOPAC) levels by electrochemical HPLC

    Striatal tissues were used for neurobiochemical analysis by electrochemical HPLC. Briefly, the striatum was weighed, and homogenized in 0.1 M perchloric acid (HClO4) containing 0.01% ethylenediamine tetraacetic acid. The homogenate was centrifuged at the speed of 10,000 × g for 10 minutes at 4°C. The supernatant was filtered through 0.22 μm filter membrane and 20 μL samples were injected into the column. Dopamine and its metabolites (DOPAC and HVA) were analyzed using a HPLC system (Agilent-1200, Wakefield, MA, USA) coupled to a 2465 electrochemical detector (Waters, Milford, MA, USA) as described previously (Zhang et al., 2014). Concentrations of dopamine and its metabolites were expressed as ng/mg tissue.

    Western blot assay

    Tissues from the substantia nigra were homogenized with radioimmunoprecipitation assay lysis buffer containing 1 mM phenylmethylsulfonyl fluoride and 1% protease inhibitor cocktail (Pierce, Rockford, IL, USA) on ice. Lysis was centrifuged at 12,500 × g for 20 minutes at 4°C. The supernatant was separated and the amount of protein was determined using the bicinchoninic acid protein assay kit (Pierce). Protein sample (30 μg) was resolved using sodium dodecyl sulfate-polyacrylamide gel electropheresis and transferred to polyvinylidene fluoride membranes. The immunoblot was analyzed with the appropriate primary antibodies (rabbit anti-mouse antibodies against tyrosine hydroxylase (TH), MEF2D, glycogen synthase kinase-3β (GSK3β), β-actin; 1:1,000) at 4°C overnight. Horseradish peroxidase-conjugated goat anti-rabbit secondary antibodies (1:2,500) at room temperature for 2 hours were used to detect the proteins of interest through enhanced chemiluminescence. All primary and secondary antibodies were purchased from Cell Signaling Technology (Beverly, MA, USA). Quantitative assessment of protein bands by densitometry was done with Gel Doc? XRS equipped with Quantity One software (Bio-Rad, Hercules, CA, USA).

    Activity of MAO-B inhibition

    MAO-B activity was determined by MAO-GloTM Assay kit (Promega, Sunnyvale, CA, USA). The recombinant human MAO-B enzyme was purchased from Sigma-Aldrich. Briefly, B3C (1 μM-10 mM) and rasagiline (10 pM-10 μM) were incubated in 96-well opaque white plates with MAO substrate and recombinant human MAO-B (0.25 mg protein/mL). Reaction was started by the addition of recombinant human MAO-B. Reaction mixture was incubated for 1 hour at room temperature. Reaction was terminated by the addition of luciferin detection reagent, and sample was incubated for an additional 20 minutes to allow the development of luciferase-dependent luminescence. Relative luminescence was determined by a plate luminometer (BioTek, Winooski, VT, USA). Results were presented as the percent of vehicle (total MAO-B activity).

    Statistical analysis

    All data are expressed as the mean ± SEM and analyzed using GraphPad Prism 5.0 (GraphPad, San Diego, CA, USA). One-way analysis of variance and Dunnett’s test were used to evaluate the statistical differences. A value of P < 0.05 was considered statistically significant.

    Results

    The effects of B3C and/or rasagiline on behavioral abnormities induced by MPTP in mice

    MPTP injection significantly induced motor abnormalities, including postural rigidity, impaired balance and coordination and gait disorder in mice. At 15thday after MPTP injection, the latency in the catalepsy test was increased by 4.8-fold (Figure 2A), the time staying on the rotarod was decreased by 57.7% (Figure 2B), and the duration of pole test was increased by 3.1 times in the MPTP-treated mice, compared to the control mice (Figure 2C). In footprint test, the time taken to cross the corridor was significantlyextended, accompanying increased step width and decreased stride length in the MPTP-treated mice, compared to the control mice (Figure 2D-F). B3C and rasagiline alone or their combination alleviated motor abnormities induced by MPTP (P < 0.05; Figure 2). Besides, neither rasagiline alone nor B3C+rasagiline co-treatment significantly reversed MPTP-induced behavioral abnormity in the rotarod test (P > 0.05; Figure 2B). In addition, there was no significant difference among B3C, rasagiline, and their combination on the reversion of motor abnormities in catalepsy, pole and footprint tests (P > 0.05).

    Figure 2 B3C, rasagiline and their combination alleviated MPTP-induced behaviour abnormities in mice.

    Figure 1 Chemical structures of bis(propyl)-cognitin (B3C) and rasagiline.

    The effects of B3C and/or rasagiline on contents of dopamine and its metabolites in the striatum of MPTP-injected mice

    Representative HPLC chromatographic peaks of dopamine and its metabolites were shown in Figure 3A. Striatal dopamine, DOPAC and HVA were significantly reduced inMPTP-treated mice when compared to control (P < 0.05; Figure 3B-D). B3C, rasagiline and their combination increased the levels of dopamine and its metabolites when compared to the MPTP group (P < 0.05). However, there was no significant difference among B3C, rasagiline and their combination (P > 0.05).

    Figure 3 B3C, rasagiline and their combination reduced MPTP-induced decrease of dopamine and its metabolites in mice.

    Figure 4 B3C, rasagiline and their combination reversed MPTP-induced decrease of TH expression in the substantia nigra (western blot assay).

    The effects of B3C and/or rasagiline on the TH expression in the substantia nigra of MPTP-injected mice

    TH was widely accepted as a marker for dopaminergic neurons (Haavik and Toska, 1998). We used western blot assay to measure the expression of TH in the substantia nigra. MPTP significantly reduced the expression of TH when compared to the control group (P < 0.05). B3C, rasagiline and their combination increased TH expression when compared to the MPTP group (P < 0.05). However, there was no significant difference among B3C, rasagiline and their combination (P > 0.05; Figure 4).

    Activities of B3C and rasagiline on MAO-B inhibition in vitro

    B3C concentration-dependently inhibited MAO-B activity with an IC50of 115.8 μM (Figure 5). Rasagiline, a wellknown selective MAO-B inhibitor, inhibited MAO-B activity with an IC50of 6.43 nM (Figure 5), which is similar to a previous report (Zheng et al., 2005).

    Regulating the expressions of GSK3β and MEF2D by B3C and/or rasagiline in the substantia nigra of MPTP-injected mice

    It was reported that MPP+could damage dopamine neurons via the inhibition of MEF2D transcriptional activity (Yao et al., 2012). MEF2D could be regulated by several signalling pathways. For example, GSK3β, an downstream molecule of PI3-K/Akt signaling pathway, could directly phosphorylate MEF2D and decrease the activity of MEF2D (Weinreb et al., 2005b; Wang et al., 2009; Yao et al., 2012). MEF2D could further protect dopamine neurons in the substantia nigra against neurotoxicity in PD animal models (Smith et al., 2006; She et al., 2011). In this study, MPTP signficanlty down-regulated the expression of MEF2D, while up-regulated the expression of GSK3β in the substantia nigra (P < 0.05; Figure 6). B3C, but not rasagiline or their combination, significantly reversed MPTP-induced alteration of GSK3β and MEF2D (P < 0.05; Figure 6).

    Discussion

    In the past decade, none of mono-drug therapies aimed to treat PD with disease-modifying potential was successful in clinical trials (Kalia et al., 2015). The multiple disease etiologies implicated in PD gave rise to a shift from a single-target to a multi-target therapy (NINDS NET-PD Investigators, 2006, 2007; Reznichenko et al., 2010).

    It has been reported that continuous administration of rasagiline (0.05 mg/kg, oral administration) following MPTP lesion restored the loss of dopaminergic neurons, the decrease of striatal dopamine content, and the reduction of TH activity (Mandel et al., 2007). Therefore, rasagiline at 0.02 and 0.1 mg/kg was used in the present study. In our study, rasagiline at both dosages was effective to treat MPTP-induced Parkinsonism, while the higher dosage did not exert greater neuroprotection. Similar results were reported by Sagi et al. (2007), showing that doubling the dose of rasagiline to 0.1 mg/kg did not lead to the greater neuroprotection. It was demonstrated that rasagiline could not produce neuroprotection at very high doses (0.25-1 mg/kg) (Sagi et al., 2007). The molecular mechanism underlying the neuroprotection of rasagiline involved the increase of protein kinase Cε, the activation of mitogen-activated protein kinase pathway, and the induction of neurotrophic factors (Yogev-Falach et al., 2003; Bar-Am et al., 2005; Weinreb et al., 2005a).

    B3C (1 mg/kg) reversed MPTP-induced loss of dopaminergic neurons and behavioral abnormitiies via effectively up-regulating MEF2D from the activation of Akt/GSK3β pathway (Yao et al., 2012). In the present study, 0.3 and 1 mg/kg B3C also alleviated behavioural abnormitiies, restored the contents of dopamine and its metabolites in the striatum, and up-regulated TH expression in the substantia nigra. To examine whether the effectiveness of B3C is associated with MAO inhibition, we have performed MAO-B activity assay. Our results showed that B3C could inhibit MAO-B with an IC50of 115.8 μM. However, B3C could effectively prevent glutamate and K+deprivation-induced neurotoxicity with an IC50at sub-nanomolar level (Luo et al., 2010; Hu et al., 2013). The concentration up to 100 μM is toxic to neurons and cannot be reached in the brain when 1 mg/kg of B3C was administrated to mice. Therefore, we deduced that the neuroprotective effects of B3C in MPTP-injected mice were independent of its MAO-B inhibition property. In consistent with the findings of a previous study (Yao et al., 2012), B3C up-regulated MEF2D and inhibited GSK3β in our study. However, rasagiline and the combination of B3C and rasagiline could not significantly alter the expressions of MEF2D and GSK3β. How could rasagiline counteract the effect of B3C on the expression of MEF2D and GSK3β? It needs to be investigated in our further study.

    The reason why there is no synergism between B3C and rasagiline is possibly due to the concentrations of drugs used in the present study. In the study of Reznichenko et al. (2010), to test the additive/synergistic action of the combination of rasagiline and EGCG in MPTP mice, low/sub-effective dosages of drugs were chosen. And individual drug at used dosage did not exert positive effects. Such experimental design could circumvent potential “masking” of the contribution of rasagiline and EGCG to the neuroprotective effects. In our study, the dosages of B3C and rasagiline were close to their maximal effective dosages. Therefore, low/sub-effective dosages are required for further investigating the synergism between B3C and rasagiline on MPTP-induced model of Parkinsonism.

    In the present study, we have investigated, for the first time, the synergistic effects between B3C and rasagiline in MPTP-induced mice model of Parkinsonism. In consistent with previous findings (Mandel et al., 2007; Sagi et al., 2007; Yao et al., 2012), both B3C and rasagiline significantly protected dopaminergic neurons against damage and reversed behavioral abnormities in MPTP-treated mice. However, the combination of B3C and rasagiline could not produce synergistic effects.

    Author contributions: ZJZ, YFH and SMYL designed the study. ZJZ and YQW wrote and revised the paper. CYZ and WC1 performed experiments and analyzed experimental data. BJG, WC2 and SHM participated in study design and performed experiments. All authors approved the final version of the paper.

    Conflicts of interest: None declared.

    Plagiarism check: This paper was screened twice using Cross-Check to verify originality before publication.

    Peer review: This paper was double-blinded and stringently reviewed by international expert reviewers.

    References

    Ahlskog JE, Uitti RJ (2010) Rasagiline, Parkinson neuroprotection, and delayed-start trials: Still no satisfaction? Neurology 74:1143-1148.

    Bao XQ, Kong XC, Qian C, Zhang D (2012) FLZ protects dopaminergic neuron through activating protein kinase B/mammalian target of rapamycin pathway and inhibiting RTP801 expression in Parkinson’s disease models. Neuroscience 202:396-404.

    Bar-Am O, Weinreb O, Amit T, Youdim MBH (2005) Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J 19:1899-1901.

    Figure 5 B3C and rasagiline inhibit MAO-B activity in vitro.

    Figure 6 B3C, rasagiline and their combination reversed MPTP-induced alteration of MEF2D and GSK3β expressions in the substantia nigra (western blot assay).

    Calabresi P, Di Filippo M (2015) Multitarget disease-modifying therapy in Parkinson’s disease? Lancet Neurol 14:975-976.

    Carlier PR, Han YF, Chow ES, Li CP, Wang H, Lieu TX, Wong HS, Pang YP (1999) Evaluation of short-tether Bis-THA AChE inhibitors. A further test of the dual binding site hypothesis. Biorg Med Chem 7:351-357.

    Degli Esposti L, Piccinni C, Sangiorgi D, Nobili F, Buda S (2015) Prescribing pattern and resource utilization of monoamine oxidase-B inhibitors in Parkinson treatment: comparison between rasagiline and selegiline. Neurol Sci 37:227-234.

    Haavik J, Toska K (1998) Tyrosine hydroxylase and Parkinson’s disease. Mol Neurobiol 16:285-309.

    Han RW, Zhang RS, Chang M, Peng YL, Wang P, Hu SQ, Choi CL, Yin M, Wang R, Han YF (2012) Reversal of scopolamine-induced spatial and recognition memory deficits in mice by novel multifunctional dimers bis-cognitins. Brain Res 1470:59-68.

    Hayley S, Crocker SJ, Smith PD, Shree T, Jackson-Lewis V, Przedborski S, Mount M, Slack R, Anisman H, Park DS (2004) Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson’s disease. J Neurosci 24:2045-2053.

    Hu SQ, Cui W, Xu DP, Mak SH, Tang J, Choi CL, Pang YP, Han YF (2013) Substantial neuroprotection against K+deprivation-induced apoptosis in primary cerebellar granule neurons by novel dimer bis(propyl)-cognitin via the activation of VEGFR-2 signaling pathway. CNS Neurosci Ther 19:764-772.

    Jackson-Lewis V, Przedborski S (2007) Protocol for the MPTP mouse model of Parkinson’s disease. Nat Protoc 2:141-151.

    Jeanjean A, Aubert G (2011) Moving pictures of Parkinson’s disease. Lancet 378:1773-1774.

    Kalia LV, Kalia SK, Lang AE (2015) Disease-modifying strategies for Parkinson’s disease. Mov Disord 30:1442-1450.

    Luo J, Li W, Zhao Y, Fu H, Ma DL, Tang J, Li C, Peoples RW, Li F, Wang Q, Huang P, Xia J, Pang Y, Han Y (2010) Pathologically activated neuroprotection via uncompetitive blockade of N-methyl-D-aspartate receptors with fast off-rate by novel multifunctional dimer bis(propyl)-cognitin. J Biol Chem 285:19947-19958.

    Mandel SA, Sagi Y, Amit T (2007) Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem Res 32:1694-1699.

    Meissner WG, Frasier M, Gasser T, Goetz CG, Lozano A, Piccini P, Obeso JA, Rascol O, Schapira A, Voon V, Weiner DM, Tison F, Bezard E (2011) Priorities in Parkinson’s disease research. Nat Rev Drug Discov 10:377-393.

    Naoi M, Maruyama W, Inaba-Hasegawa K (2013) Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms. Expert Rev Neurother 13:671-684.

    NINDS NET-PD Investigators (2006) A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 66:664-671.

    NINDS NET-PD Investigators (2007) A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 68:20-28.

    Ogawa N, Hirose Y, Ohara S, Ono T, Watanabe Y (1985) A simple quantitative bradykinesia test in MPTP-treated mice. Res Commun Chem Pathol Pharmacol 50:435-441.

    Reznichenko L, Kalfon L, Amit T, Youdim MB, Mandel SA (2010) Low dosage of rasagiline and epigallocatechin gallate synergistically restored the nigrostriatal axis in MPTP-induced parkinsonism. Neurodegener Dis 7:219-231.

    Richter F, Hamann M, Richter A (2007) Chronic rotenone treatment induces behavioral effects but no pathological signs of parkinsonism in mice. J Neurosci Res 85:681-691.

    Sagi Y, Mandel S, Amit T, Youdim MB (2007) Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol Dis 25:35-44.

    Schapira AH (2004) Disease modification in Parkinson’s disease. Lancet Neurol 3:362-368.

    Sedelis M, Schwarting RK, Huston JP (2001) Behavioral phenotyping of the MPTP mouse model of Parkinson’s disease. Behav Brain Res 125:109-125.

    She H, Yang Q, Shepherd K, Smith Y, Miller G, Testa C, Mao Z (2011) Direct regulation of complex I by mitochondrial MEF2D is disrupted in a mouse model of Parkinson disease and in human patients. J Clin Invest 121:930-940.

    Smith K (2010) Treatment frontiers. Nature 466:S15-S18.

    Smith PD, Mount MP, Shree R, Callaghan S, Slack RS, Anisman H, Vincent I, Wang X, Mao Z, Park DS (2006) Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. J Neurosci 26:440-447.

    Tatton WG, Greenwood CE (1991) Rescue of dying neurons: a new action for deprenyl in MPTP parkinsonism. J Neurosci Res 30:666-672.

    Wang X, She H, Mao Z (2009) Phosphorylation of neuronal survival factor MEF2D by glycogen synthase kinase 3beta in neuronal apoptosis. J Biol Chem 284:32619-32626.

    Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB (2005a) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathwa. Ann N Y Acad Sci 1053:348-355.

    Weinreb O, Amit T, Bar-Am O, Chillag-Talmor O, Youdim MB (2005b) Novel neuroprotective mechanism of action of rasagiline is associated with its propargyl moiety: interaction of Bcl-2 family members with PKC pathway. Ann N Y Acad Sci 1053:348-355.

    Yao L, Li W, She H, Dou J, Jia L, He Y, Yang Q, Zhu J, Cápiro NL, Walker DI, Pennell KD, Pang Y, Liu Y, Han Y, Mao Z (2012) Activation of transcription factor MEF2D by bis(3)-cognitin protects dopaminergic neurons and ameliorates Parkinsonian motor defects. J Biol Chem 287:34246-34255.

    Yogev-Falach M, Amit T, Bar-Am O, Youdim MB (2003) The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J 17:2325-2327.

    Youdim MBH, Wadia A, Tatton W, Weinstock M (2001) The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann N Y Acad Sci 939:450-458.

    Zhang Z, Lai D, Wang L, Yu P, Zhu L, Guo B, Xu L, Zhou L, Sun Y, Lee SM, Wang Y (2014) Neuroprotective effects of the andrographolide analogue AL-1 in the MPP+/MPTP-induced Parkinson’s disease model in vitro and in mice. Pharmacol Biochem Behav 122:191-202.

    Zhang Z, Li G, Szeto SS, Chong CM, Quan Q, Huang C, Cui W, Guo B, Wang Y, Han Y, Michael Siu KW, Yuen Lee SM, Chu IK (2015) Examining the neuroprotective effects of protocatechuic acid and chrysin on in vitro and in vivo models of Parkinson disease. Free Radic Biol Med 84:331-343.

    Zheng H, Gal S, Weiner LM, Bar-Am O, Warshawsky A, Fridkin M, Youdim MB (2005) Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: in vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J Neurochem 95:68-78.

    Copyedited by Yu J, Qiu Y, Li CH, Song LP, Zhao M

    10.4103/1673-5374.189201

    *Correspondence to:

    久久久国产欧美日韩av| 国产黄频视频在线观看| 国产国语露脸激情在线看| 亚洲精品国产一区二区精华液| 久久国产亚洲av麻豆专区| 国产亚洲av高清不卡| 午夜福利视频在线观看免费| 男女之事视频高清在线观看| 黄色片一级片一级黄色片| 黄色a级毛片大全视频| 国产精品98久久久久久宅男小说| 国产在线观看jvid| 99国产精品一区二区蜜桃av | xxxhd国产人妻xxx| 女人被躁到高潮嗷嗷叫费观| 日韩三级视频一区二区三区| 99热国产这里只有精品6| 欧美久久黑人一区二区| 一级黄色大片毛片| 亚洲成人国产一区在线观看| 91字幕亚洲| 天堂动漫精品| 超色免费av| 色尼玛亚洲综合影院| 五月天丁香电影| 精品亚洲成国产av| 男女免费视频国产| 欧美另类亚洲清纯唯美| av免费在线观看网站| 国产日韩欧美在线精品| 交换朋友夫妻互换小说| 多毛熟女@视频| 在线 av 中文字幕| 国产真人三级小视频在线观看| 欧美激情高清一区二区三区| 成人国产av品久久久| 成年人免费黄色播放视频| 国产黄色免费在线视频| 国产精品一区二区免费欧美| 老汉色∧v一级毛片| 亚洲,欧美精品.| 纵有疾风起免费观看全集完整版| 熟女少妇亚洲综合色aaa.| 午夜福利影视在线免费观看| tube8黄色片| 亚洲av电影在线进入| 国产欧美日韩综合在线一区二区| 99国产精品99久久久久| 丝袜喷水一区| 国产精品 国内视频| 91麻豆av在线| 国产精品99久久99久久久不卡| 巨乳人妻的诱惑在线观看| 国产免费福利视频在线观看| 欧美成人免费av一区二区三区 | 亚洲欧美日韩另类电影网站| 亚洲成av片中文字幕在线观看| 丝袜人妻中文字幕| 国产精品 欧美亚洲| 水蜜桃什么品种好| 久久av网站| 超色免费av| 黑人欧美特级aaaaaa片| 亚洲熟女毛片儿| 亚洲av美国av| 最黄视频免费看| 窝窝影院91人妻| 久久久久久久大尺度免费视频| 日本黄色日本黄色录像| 国产欧美日韩一区二区精品| 欧美日韩国产mv在线观看视频| 精品人妻1区二区| 性高湖久久久久久久久免费观看| 日本撒尿小便嘘嘘汇集6| 王馨瑶露胸无遮挡在线观看| 啦啦啦免费观看视频1| 男女下面插进去视频免费观看| 欧美成人免费av一区二区三区 | 另类精品久久| 国产精品九九99| 国产欧美日韩综合在线一区二区| av不卡在线播放| 巨乳人妻的诱惑在线观看| 人成视频在线观看免费观看| 午夜免费鲁丝| 国产野战对白在线观看| 天堂中文最新版在线下载| 日韩中文字幕视频在线看片| 久久国产精品影院| 国产主播在线观看一区二区| 在线看a的网站| 精品午夜福利视频在线观看一区 | 岛国毛片在线播放| 国产单亲对白刺激| 侵犯人妻中文字幕一二三四区| 久久天堂一区二区三区四区| 久久九九热精品免费| 我的亚洲天堂| 韩国精品一区二区三区| 18禁美女被吸乳视频| 婷婷丁香在线五月| 一区二区三区激情视频| videosex国产| 午夜激情久久久久久久| 欧美日韩黄片免| 亚洲精品美女久久av网站| 如日韩欧美国产精品一区二区三区| 久久久久久久久免费视频了| 韩国精品一区二区三区| 欧美精品人与动牲交sv欧美| 精品一区二区三区av网在线观看 | 亚洲黑人精品在线| av一本久久久久| 午夜两性在线视频| 久久中文看片网| 中文字幕人妻熟女乱码| 不卡av一区二区三区| 久热这里只有精品99| 汤姆久久久久久久影院中文字幕| 日日夜夜操网爽| 日韩免费av在线播放| 90打野战视频偷拍视频| 欧美一级毛片孕妇| 日韩中文字幕欧美一区二区| 成在线人永久免费视频| av网站在线播放免费| 麻豆成人av在线观看| 十八禁网站网址无遮挡| 菩萨蛮人人尽说江南好唐韦庄| 我要看黄色一级片免费的| 99re在线观看精品视频| 亚洲一卡2卡3卡4卡5卡精品中文| 超碰成人久久| 另类亚洲欧美激情| 久久久国产成人免费| 在线观看舔阴道视频| 亚洲第一av免费看| 久久性视频一级片| 亚洲av片天天在线观看| 亚洲视频免费观看视频| 亚洲一卡2卡3卡4卡5卡精品中文| 激情在线观看视频在线高清 | 久久九九热精品免费| 成人精品一区二区免费| 久久精品国产亚洲av香蕉五月 | 免费在线观看日本一区| 国产成人系列免费观看| 青草久久国产| 亚洲自偷自拍图片 自拍| 欧美变态另类bdsm刘玥| 99香蕉大伊视频| 一本大道久久a久久精品| 国产精品久久久人人做人人爽| 国产又爽黄色视频| 亚洲熟女精品中文字幕| 精品卡一卡二卡四卡免费| 久久国产精品男人的天堂亚洲| a在线观看视频网站| 亚洲色图综合在线观看| 搡老岳熟女国产| 日韩大码丰满熟妇| 国产亚洲精品一区二区www | 91国产中文字幕| 亚洲精品自拍成人| 日日爽夜夜爽网站| 精品一品国产午夜福利视频| 91国产中文字幕| 9191精品国产免费久久| av欧美777| 如日韩欧美国产精品一区二区三区| 在线观看舔阴道视频| 亚洲精品久久成人aⅴ小说| 制服诱惑二区| 久久精品亚洲精品国产色婷小说| a级片在线免费高清观看视频| 一进一出抽搐动态| 在线观看66精品国产| 精品少妇黑人巨大在线播放| 91麻豆av在线| 自线自在国产av| 69av精品久久久久久 | 大香蕉久久网| 一级片'在线观看视频| 超碰97精品在线观看| 国产男女超爽视频在线观看| 久久人人爽av亚洲精品天堂| 美女午夜性视频免费| 国产色视频综合| 99九九在线精品视频| 国产主播在线观看一区二区| e午夜精品久久久久久久| 精品少妇一区二区三区视频日本电影| 天天添夜夜摸| 精品一区二区三区av网在线观看 | 三级毛片av免费| 精品福利观看| 日韩视频一区二区在线观看| 50天的宝宝边吃奶边哭怎么回事| 国产淫语在线视频| 国产精品美女特级片免费视频播放器 | 亚洲av成人不卡在线观看播放网| 欧美日韩成人在线一区二区| 不卡av一区二区三区| 国产精品二区激情视频| 老司机午夜福利在线观看视频 | 国产成人精品无人区| 脱女人内裤的视频| 1024香蕉在线观看| 亚洲国产欧美在线一区| www.自偷自拍.com| 欧美成狂野欧美在线观看| 亚洲专区字幕在线| 久久久久精品人妻al黑| 国产高清国产精品国产三级| 久久久国产欧美日韩av| 久久九九热精品免费| 欧美 亚洲 国产 日韩一| 91精品三级在线观看| 91麻豆av在线| 男女午夜视频在线观看| 成人黄色视频免费在线看| 日韩免费高清中文字幕av| 欧美老熟妇乱子伦牲交| 777米奇影视久久| 欧美日韩av久久| 国产三级黄色录像| 国产精品一区二区免费欧美| 精品视频人人做人人爽| 欧美黄色淫秽网站| 午夜精品国产一区二区电影| 99国产精品一区二区蜜桃av | 老熟女久久久| 国产精品偷伦视频观看了| 一级毛片女人18水好多| 国产xxxxx性猛交| 精品熟女少妇八av免费久了| 亚洲成人免费电影在线观看| 国内毛片毛片毛片毛片毛片| 高潮久久久久久久久久久不卡| 精品一区二区三卡| 亚洲伊人久久精品综合| 色老头精品视频在线观看| 岛国毛片在线播放| 亚洲欧美日韩高清在线视频 | 91老司机精品| 一进一出好大好爽视频| 中文字幕色久视频| 丝瓜视频免费看黄片| 国产成人精品久久二区二区91| 少妇的丰满在线观看| 国产精品 欧美亚洲| 99久久精品国产亚洲精品| 亚洲情色 制服丝袜| 不卡av一区二区三区| 波多野结衣av一区二区av| 欧美激情极品国产一区二区三区| 国产成人一区二区三区免费视频网站| 男男h啪啪无遮挡| 丰满饥渴人妻一区二区三| 少妇被粗大的猛进出69影院| 亚洲精品自拍成人| 国产成人av激情在线播放| 18禁观看日本| 欧美日韩中文字幕国产精品一区二区三区 | 久久国产精品男人的天堂亚洲| 国产精品久久久久久人妻精品电影 | 国产1区2区3区精品| 日韩制服丝袜自拍偷拍| 久久中文字幕人妻熟女| 老司机午夜福利在线观看视频 | 国产精品 国内视频| 午夜日韩欧美国产| 亚洲成av片中文字幕在线观看| 亚洲国产中文字幕在线视频| 日韩视频在线欧美| 国产麻豆69| 热re99久久精品国产66热6| 欧美激情高清一区二区三区| 91九色精品人成在线观看| 亚洲久久久国产精品| 色尼玛亚洲综合影院| 欧美av亚洲av综合av国产av| 桃花免费在线播放| 国产男靠女视频免费网站| 国产精品久久久久久人妻精品电影 | 国产一区二区三区综合在线观看| 国产黄频视频在线观看| 人人澡人人妻人| 久久精品成人免费网站| 久久香蕉激情| 国产av国产精品国产| 国产不卡一卡二| 精品国产乱码久久久久久小说| 国产精品1区2区在线观看. | 国产免费av片在线观看野外av| 日本wwww免费看| 国产一区二区 视频在线| 午夜福利视频在线观看免费| 久久午夜亚洲精品久久| 黄色毛片三级朝国网站| 巨乳人妻的诱惑在线观看| 久久久国产成人免费| av不卡在线播放| 大香蕉久久网| 久久久久精品国产欧美久久久| 日本五十路高清| 国产成人精品久久二区二区91| 看免费av毛片| 一区福利在线观看| 国产精品秋霞免费鲁丝片| 一级a爱视频在线免费观看| 国产亚洲欧美在线一区二区| 搡老乐熟女国产| 飞空精品影院首页| 电影成人av| 欧美精品av麻豆av| 国产高清视频在线播放一区| cao死你这个sao货| 色播在线永久视频| 热99久久久久精品小说推荐| 99香蕉大伊视频| 天天躁日日躁夜夜躁夜夜| 考比视频在线观看| bbb黄色大片| 成年人午夜在线观看视频| a级片在线免费高清观看视频| 视频区图区小说| 亚洲中文字幕日韩| 精品国产一区二区三区久久久樱花| 色综合欧美亚洲国产小说| 男人舔女人的私密视频| 久久久久久久精品吃奶| 精品国内亚洲2022精品成人 | 成人国产一区最新在线观看| 久久亚洲真实| 啦啦啦视频在线资源免费观看| 日韩精品免费视频一区二区三区| 日本撒尿小便嘘嘘汇集6| 动漫黄色视频在线观看| 国产免费福利视频在线观看| 成人18禁高潮啪啪吃奶动态图| 男女午夜视频在线观看| 啪啪无遮挡十八禁网站| 少妇猛男粗大的猛烈进出视频| 精品视频人人做人人爽| a在线观看视频网站| 国产精品一区二区免费欧美| 十八禁高潮呻吟视频| 久久天躁狠狠躁夜夜2o2o| 国产成人精品久久二区二区免费| 亚洲少妇的诱惑av| 久久久国产成人免费| 国产精品一区二区精品视频观看| 19禁男女啪啪无遮挡网站| 国产精品 欧美亚洲| 美女国产高潮福利片在线看| 岛国毛片在线播放| 午夜久久久在线观看| 嫩草影视91久久| 两性夫妻黄色片| 国产精品国产高清国产av | 精品乱码久久久久久99久播| 亚洲国产欧美在线一区| 久久久久久久国产电影| 久久久水蜜桃国产精品网| 女警被强在线播放| 99国产精品一区二区三区| 亚洲成人国产一区在线观看| 一区二区三区精品91| 国产高清国产精品国产三级| 丝袜在线中文字幕| 亚洲欧美一区二区三区黑人| 国精品久久久久久国模美| 天天躁狠狠躁夜夜躁狠狠躁| 99热国产这里只有精品6| 女性被躁到高潮视频| 人妻一区二区av| 精品久久蜜臀av无| 美女国产高潮福利片在线看| 国产成人精品在线电影| 丰满人妻熟妇乱又伦精品不卡| 十八禁高潮呻吟视频| 亚洲一卡2卡3卡4卡5卡精品中文| 精品国产国语对白av| avwww免费| 香蕉国产在线看| 欧美性长视频在线观看| 久久久久精品人妻al黑| 性少妇av在线| 老汉色∧v一级毛片| 桃红色精品国产亚洲av| 曰老女人黄片| 老司机影院毛片| 中文字幕最新亚洲高清| 日韩免费av在线播放| 青草久久国产| 一本大道久久a久久精品| videosex国产| av天堂久久9| 国产精品久久久av美女十八| 老鸭窝网址在线观看| 亚洲中文日韩欧美视频| av视频免费观看在线观看| 熟女少妇亚洲综合色aaa.| 午夜福利一区二区在线看| 久久午夜综合久久蜜桃| 19禁男女啪啪无遮挡网站| 中文字幕高清在线视频| 男女之事视频高清在线观看| 午夜激情av网站| 男女边摸边吃奶| 丰满饥渴人妻一区二区三| 久9热在线精品视频| 成人国产一区最新在线观看| 少妇的丰满在线观看| avwww免费| 国产高清国产精品国产三级| 成年人免费黄色播放视频| 色播在线永久视频| 国产福利在线免费观看视频| 国产精品亚洲一级av第二区| 69精品国产乱码久久久| 十八禁高潮呻吟视频| 大码成人一级视频| 1024香蕉在线观看| 免费一级毛片在线播放高清视频 | 国产亚洲午夜精品一区二区久久| 午夜福利,免费看| 中文字幕av电影在线播放| videosex国产| 老司机亚洲免费影院| 午夜福利在线观看吧| 成人特级黄色片久久久久久久 | 侵犯人妻中文字幕一二三四区| 91国产中文字幕| 午夜精品国产一区二区电影| 少妇的丰满在线观看| 人妻 亚洲 视频| 91老司机精品| 成在线人永久免费视频| 成年版毛片免费区| 男人操女人黄网站| 国产亚洲精品第一综合不卡| 亚洲欧洲日产国产| 久久久久精品人妻al黑| 女人爽到高潮嗷嗷叫在线视频| 一夜夜www| 777久久人妻少妇嫩草av网站| 丝袜人妻中文字幕| 亚洲 国产 在线| 桃花免费在线播放| 免费高清在线观看日韩| 国产老妇伦熟女老妇高清| 中亚洲国语对白在线视频| 另类精品久久| 夜夜夜夜夜久久久久| 美女午夜性视频免费| av天堂久久9| 国产午夜精品久久久久久| 亚洲国产欧美网| 国产成人精品无人区| 黄网站色视频无遮挡免费观看| 操出白浆在线播放| 国产xxxxx性猛交| 91大片在线观看| 国产免费av片在线观看野外av| 久久青草综合色| 脱女人内裤的视频| 精品少妇黑人巨大在线播放| 9色porny在线观看| 亚洲精品一二三| 精品免费久久久久久久清纯 | 母亲3免费完整高清在线观看| 在线观看免费高清a一片| 天天躁夜夜躁狠狠躁躁| 成人黄色视频免费在线看| 999精品在线视频| 操出白浆在线播放| 亚洲全国av大片| 日韩人妻精品一区2区三区| 亚洲色图av天堂| 日韩视频一区二区在线观看| 精品卡一卡二卡四卡免费| 十八禁网站网址无遮挡| xxxhd国产人妻xxx| 国产淫语在线视频| 一本色道久久久久久精品综合| 精品亚洲成国产av| 成人国产av品久久久| 久久久久久久久久久久大奶| 999精品在线视频| 日韩大片免费观看网站| 久久中文看片网| 精品卡一卡二卡四卡免费| 欧美精品人与动牲交sv欧美| 国产欧美日韩一区二区三区在线| 人妻久久中文字幕网| 99精品欧美一区二区三区四区| 咕卡用的链子| 色精品久久人妻99蜜桃| 日韩制服丝袜自拍偷拍| 久久久精品94久久精品| 国产在线免费精品| 欧美国产精品va在线观看不卡| 国产精品成人在线| 极品少妇高潮喷水抽搐| 国产aⅴ精品一区二区三区波| 女人久久www免费人成看片| 国产精品熟女久久久久浪| 成年人黄色毛片网站| 无遮挡黄片免费观看| 国产日韩一区二区三区精品不卡| 亚洲九九香蕉| 精品国产亚洲在线| 亚洲免费av在线视频| 宅男免费午夜| 成人永久免费在线观看视频 | 男人舔女人的私密视频| 欧美中文综合在线视频| 日韩熟女老妇一区二区性免费视频| 91九色精品人成在线观看| 最新的欧美精品一区二区| av天堂在线播放| 搡老乐熟女国产| 99精国产麻豆久久婷婷| 一边摸一边做爽爽视频免费| 桃花免费在线播放| 人人妻人人爽人人添夜夜欢视频| 我要看黄色一级片免费的| 久久九九热精品免费| 亚洲国产毛片av蜜桃av| 精品国产乱子伦一区二区三区| 日本a在线网址| 热re99久久精品国产66热6| 十分钟在线观看高清视频www| 久久中文看片网| 一本综合久久免费| 超色免费av| 成人av一区二区三区在线看| 亚洲avbb在线观看| 国产免费现黄频在线看| 一二三四在线观看免费中文在| 女警被强在线播放| 少妇被粗大的猛进出69影院| 亚洲欧美一区二区三区久久| 大香蕉久久成人网| 国产日韩欧美在线精品| 亚洲精品久久午夜乱码| 交换朋友夫妻互换小说| 黑人巨大精品欧美一区二区蜜桃| 国产人伦9x9x在线观看| 国内毛片毛片毛片毛片毛片| 亚洲精品中文字幕在线视频| 久久久国产一区二区| 美女高潮到喷水免费观看| 亚洲色图av天堂| 久久这里只有精品19| 国产精品久久久人人做人人爽| 99九九在线精品视频| 久久精品亚洲av国产电影网| 亚洲第一av免费看| 久久 成人 亚洲| 久久久久久久精品吃奶| 欧美+亚洲+日韩+国产| 国产人伦9x9x在线观看| 肉色欧美久久久久久久蜜桃| 悠悠久久av| svipshipincom国产片| 99精国产麻豆久久婷婷| 久久久久久免费高清国产稀缺| 精品午夜福利视频在线观看一区 | av又黄又爽大尺度在线免费看| 久久精品国产亚洲av香蕉五月 | 久久久久久久大尺度免费视频| av网站在线播放免费| 成人免费观看视频高清| 黄色视频在线播放观看不卡| 欧美成狂野欧美在线观看| 国产深夜福利视频在线观看| 法律面前人人平等表现在哪些方面| 人人妻人人澡人人爽人人夜夜| 欧美日韩精品网址| 91国产中文字幕| 欧美+亚洲+日韩+国产| 黑人猛操日本美女一级片| 俄罗斯特黄特色一大片| 久久婷婷成人综合色麻豆| 午夜久久久在线观看| 黄色视频,在线免费观看| 亚洲精品中文字幕在线视频| 亚洲国产中文字幕在线视频| 日韩视频一区二区在线观看| 国产一区二区三区视频了| 亚洲国产中文字幕在线视频| 亚洲性夜色夜夜综合| 在线观看www视频免费| 老司机福利观看| 免费高清在线观看日韩| 国产精品久久久久久精品古装| 午夜久久久在线观看| 亚洲九九香蕉| 老熟妇仑乱视频hdxx| 国产精品一区二区在线不卡| 精品免费久久久久久久清纯 | 国产精品自产拍在线观看55亚洲 | 亚洲熟妇熟女久久| 又紧又爽又黄一区二区| 亚洲第一欧美日韩一区二区三区 | 午夜免费鲁丝| 亚洲精华国产精华精| 久久久国产欧美日韩av| 日日摸夜夜添夜夜添小说| a在线观看视频网站| 亚洲国产看品久久| 大片免费播放器 马上看|